Research
Hormonal
Irisin has anti-inflammatory properties in adipose tissue, suppressing pro-inflammatory cytokines and promoting the switching of macrophages from a pro-inflammatory (M1) to an anti-inflammatory (M2) state.
Managing obesity reduces systemic inflammation. While irisin contributes to this anti-inflammatory effect, the primary benefit comes from overall weight loss and exercise, not from targeting inflammation via irisin alone.
ModerateSupportsMEDIUM confidence
Irisin treatment suppressed expression of pro-inflammatory cytokines, nuclear factor-kappa B (NF-κB), TNF-α, and IL-6 in a concentration dependent manner... irisin induced the phenotypic switching of adipose tissue macrophages from M1 (pro-inflammatory) to M2 (anti-inflammatory) state.
Why this rating
Evidence is primarily from in vitro and animal models; human data on inflammatory markers is correlational and inconsistent.
Source
Irisin: A Hope in Understanding and Managing Obesity and Metabolic Syndrome
Lidia Iuliana Arhire et al. · Frontiers in Endocrinology · 2019
DOI 10.3389/fendo.2019.00524
narrative_reviewCited 304×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Exercise-induced irisin promotes the browning of white adipose tissue and increases energy expenditure, offering a potential therapeutic mechanism for managing obesity and metabolic syndrome.Moderate
- Irisin acts as an insulin-sensitizing hormone that facilitates glucose uptake in skeletal muscle and improves hepatic glucose metabolism, potentially reducing the risk of type 2 diabetes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →